PL-3994

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C82H127N27O20S2
Molecular Weight	1875.185
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCC(=O)N[C@@H]1CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCCC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CNC=N3)NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)N5C[C@@H](NC(=O)[C@@H]5CCCNC(N)=N)C(N)=O

InChI

InChIKey=HSHVZRILAMZYHY-WXSGKXQHSA-N

InChI=1S/C82H127N27O20S2/c1-6-9-11-15-25-62(112)98-59-41-130-131-42-60(76(126)104-56(34-47-26-28-49(111)29-27-47)79(129)109-39-57(66(83)116)105-77(127)61(109)24-18-32-93-82(88)89)107-74(124)58(40-110)106-78(128)65(44(4)8-3)108-70(120)52(23-17-31-92-81(86)87)100-73(123)55(36-64(114)115)103-69(119)51(21-10-7-2)99-68(118)50(22-16-30-91-80(84)85)97-63(113)38-94-67(117)45(5)96-71(121)53(33-46-19-13-12-14-20-46)101-72(122)54(102-75(59)125)35-48-37-90-43-95-48/h12-14,19-20,26-29,37,43-45,50-61,65,110-111H,6-11,15-18,21-25,30-36,38-42H2,1-5H3,(H2,83,116)(H,90,95)(H,94,117)(H,96,121)(H,97,113)(H,98,112)(H,99,118)(H,100,123)(H,101,122)(H,102,125)(H,103,119)(H,104,126)(H,105,127)(H,106,128)(H,107,124)(H,108,120)(H,114,115)(H4,84,85,91)(H4,86,87,92)(H4,88,89,93)/t44-,45+,50-,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,65-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23154072 | DOI: 10.1016/j.cardfail.2009.06.207 | DOI: 10.1016/j.cardfail.2008.06.188 | https://adisinsight.springer.com/drugs/800022788 | Tsioufis, C. et al. (2016) Interventional Therapies for Secondary and Essential Hypertension, page 168, retrieved from: https://books.google.ru/books?id=MFfYDAAAQBAJ

PL-3994 is a novel natriuretic cyclic peptide. It is a receptor-A (NPR-A) and receptor-C (NPR-C) agonist. PL-3994 has high affinity for recombinant human, dog, or rat NPR-As. PL-3994 produced concentration-dependent relaxation of pre-contracted guinea-pig trachea. PL-3994 elicited a potent, concentration-dependent but small relaxation of pre-contracted human precision-cut lung slices. Intratracheal PL-3994 produced a dose-dependent inhibition of the bronchoconstrictor response evoked by aerosolized methacholine, but was without significant effect on cardiovascular parameters. PL-3994 was resistant to degradation by human neutral endopeptidase. PL-3994 was well tolerated in subjects with controlled hypertension. A phase I and phase II trial have been successfully completed with PL-3994 with no safety concerns identified. In phase II study in subjects with hypertension who were receiving >1 antihypertensive medications, a significant reduction in blood pressure compared with placebo was observed. It appears that PL-3994 works synergistically with ACE inhibitors.

Originator

Approval Year

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

Single dose - 0.3 ug/kg

Route of Administration: Other

Name

Type

Language

PL-3994

Common Name

English

(HEPT-CYCLO(CYS-HIS-PHE-D-ALA-GLY-ARG-D-NLE-ASP-ARG-ILE-SER-CYS)-TYR-(ARG MIMETIC)-NH2)

Systematic Name

English

2-((4R,7S,10S,13R,16R,19R,22R,28R,31S,34S,37S)-31-BENZYL-19-BUTYL-4-(((1S)-2-((2S,5R)-5-CARBAMOYL-2-(3-GUANIDINOPROPYL)-3-OXO-PIPERAZIN-1-YL)-1-((4-HYDROXYPHENYL)METHYL)-2-OXO-ETHYL)CARBAMOYL)-13,22-BIS(3-GUANIDINOPROPYL)-37-(HEPTANOYLAMINO)-7-(HYDROXYME

Systematic Name

English

Code System Code Type Description

FDA UNII

YI2S0GUQ2C

Created by admin on Sat Dec 16 11:36:49 GMT 2023 , Edited by admin on Sat Dec 16 11:36:49 GMT 2023

PRIMARY

CAS

952295-80-6

Created by admin on Sat Dec 16 11:36:49 GMT 2023 , Edited by admin on Sat Dec 16 11:36:49 GMT 2023

PRIMARY

DRUG BANK

DB15355

Created by admin on Sat Dec 16 11:36:49 GMT 2023 , Edited by admin on Sat Dec 16 11:36:49 GMT 2023

PRIMARY

PUBCHEM

121488161

Created by admin on Sat Dec 16 11:36:49 GMT 2023 , Edited by admin on Sat Dec 16 11:36:49 GMT 2023

PRIMARY

ACTIVE MOIETY


					YI2S0GUQ2C

PL-3994